Advanced High-Grade Serous Ovarian Cancer Treated With Intensive Cytoreductive Surgery And Chemotherapy: Prognostic Impact Of Lymph Node Involvement: Analysis Of The French National ESME-Unicancer Database
Cécile Loaec(Institut de Cancérologie de l'Ouest), Barnabé Bouvarel(Institut de Cancérologie de l'Ouest), E. Martin(Institut de Cancérologie de l'Ouest), Hélène Costaz(Centre Georges François Leclerc), Enora Laas(Institut Curie), Pierre‐Emmanuel Colombo(Inserm), L. Bosquet(UniCancer Group), L. Rossi(Centre Léon Bérard), Quentin Dominique Thomas(Université de Montpellier), Christophe Pomel(Université Clermont Auvergne), Éric Lambaudie, Fabrice Narducci(Centre Oscar Lambret), Roman Rouzier(Institut Curie), Sébastien Gouy(Inserm), Thibault De La Motte Rouge(Inserm), Thierry Petit, S. Le Bars(Institut de Cancérologie de l'Ouest), Jean-Marc Classe(Institut de Cancérologie de l'Ouest), Laurence Gladieff(Institut Claudius Regaud), Catherine Guerin-Charbonneli(Institut de Cancérologie de l'Ouest), Frédéric Marchal(Institut de Cancérologie de Lorraine)
Cited by 0
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer
|International Journal of Gynecological Cancer|2020|298
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
|European Journal of Cancer|2021|174